"$70 million" windfall recovered from Biogen Idec dwarfs Vernalis' market cap
This article was originally published in Scrip
Executive Summary
As Vernalis regained the rights to the A2A receptor antagonist programme for Parkinson's disease from Biogen Idec, the deal served to illustrate the gap between the spending on an asset and the value of that asset. Vernalis CEO Ian Garland told Scrip that he believes Biogen Idec has invested around $70 million in the programme over the last 4-5 years. However, the lead molecule from the programme, V81444, is only "Phase I-ready", having received MHRA approval for first dosing in man. At the same time, investors are currently valuing the whole of Vernalis, including V81444, at approximately £39 million.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.